Dermatology Department, St Vincent's University Hospital, Elm Park, Dublin 4, Ireland.
Expert Rev Clin Immunol. 2014 Feb;10(2):269-79. doi: 10.1586/1744666X.2014.873701. Epub 2013 Dec 27.
This review focuses on the efficacy, safety and best use of biologic agents in moderate-to-severe psoriasis. Recommendations from two recent guidelines are summarised. The NICE Guidelines 2012 provide recommendations on best practice for prescribing biologics. The German S3 Guidelines are based on a systematic review of published studies and report the efficacy of biologics and guidelines for treatment. Data on the safety of biologics are available for up to 5 years in psoriasis and are on the whole reassuring. Registry data is evolving and will provide data on safety to help inform long-term monitoring of patients with psoriasis on biologics agents. New anti-interleukin-17 (IL17) and anti-IL17RA biologics are in Phase 3 clinical trials and may prove to be more effective than existing biologics.
这篇综述重点介绍了生物制剂治疗中重度银屑病的疗效、安全性和最佳应用。总结了最近两项指南的建议。2012 年 NICE 指南提供了关于生物制剂处方最佳实践的建议。德国 S3 指南基于对已发表研究的系统评价，报告了生物制剂的疗效和治疗指南。在银屑病中，生物制剂的安全性数据可长达 5 年，总体上是令人放心的。注册数据正在不断发展，并将提供安全性数据，以帮助为接受生物制剂治疗的银屑病患者的长期监测提供信息。新型抗白细胞介素-17（IL17）和抗白细胞介素-17RA 生物制剂处于 3 期临床试验阶段，可能比现有生物制剂更有效。
